Aging medicine (Milton (N.S.W)) · 2026
Reduced CB1 Cannabinoid Receptor Expression in Alzheimer's Disease and Transgenic Mouse Models.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
von Borcke Nike, Purwien Amrei Vivian, Steiert Annik, Hasecke Henrike, Bouter Yvonne
Аннотация
OBJECTIVES: Therefore, in the present study, the CB1 receptor (CB1R) expression in the hippocampal and cortical tissue of a clinically and neuropathologically characterized cohort of AD patients was analyzed.
METHODS: Post-mortem brain tissue from patients with sporadic AD and non-demented control subjects was analyzed immunohistochemically, focusing on the hippocampus, medial frontal gyrus, and superior temporal gyrus. CB1R expression levels were measured and correlated with neuropathological hallmarks of AD (amyloid-β and tau pathology), neuroinflammatory markers (GFAP and IBA1), cognitive status (Reisberg scale), ApoE genotype, and age. Complementary analyzes were performed in two AD mouse models (5xFAD and Tg4-42).
RESULTS: CB1R expression was significantly reduced in the hippocampus, medial frontal gyrus, and superior temporal gyrus of AD patients. CB1R levels negatively correlated with both amyloid-β and tau pathology but showed no association with cognitive performance, neuroinflammatory markers, age, or ApoE genotype. Consistent with the human findings, CB1R expression was also reduced in the cortex of 5xFAD mice and in the hippocampus of Tg4-42 mice.
CONCLUSIONS: Our data demonstrate a region-specific downregulation of CB1R in both human AD brains and transgenic mouse models, which correlates with key neuropathological hallmarks of the disease. These findings suggest a potential role for CB1R in AD pathophysiology and support further investigation into its utility as a biomarker or therapeutic target.
METHODS: Post-mortem brain tissue from patients with sporadic AD and non-demented control subjects was analyzed immunohistochemically, focusing on the hippocampus, medial frontal gyrus, and superior temporal gyrus. CB1R expression levels were measured and correlated with neuropathological hallmarks of AD (amyloid-β and tau pathology), neuroinflammatory markers (GFAP and IBA1), cognitive status (Reisberg scale), ApoE genotype, and age. Complementary analyzes were performed in two AD mouse models (5xFAD and Tg4-42).
RESULTS: CB1R expression was significantly reduced in the hippocampus, medial frontal gyrus, and superior temporal gyrus of AD patients. CB1R levels negatively correlated with both amyloid-β and tau pathology but showed no association with cognitive performance, neuroinflammatory markers, age, or ApoE genotype. Consistent with the human findings, CB1R expression was also reduced in the cortex of 5xFAD mice and in the hippocampus of Tg4-42 mice.
CONCLUSIONS: Our data demonstrate a region-specific downregulation of CB1R in both human AD brains and transgenic mouse models, which correlates with key neuropathological hallmarks of the disease. These findings suggest a potential role for CB1R in AD pathophysiology and support further investigation into its utility as a biomarker or therapeutic target.